G Sachs has maintained a 'Buy' rating on INNOCARE due to the company's strong sales performance, particularly a 27% year-over-year increase in Orelabrutinib sales in Q4, and an expected 41% increase in sales for 2025. The company is projected to achieve profitability in 2025, two years earlier than anticipated, and management is confident in maintaining profitability through 2026-2027. Although net profit forecasts for 2026-2028 have been slightly revised down due to increased R&D expenses, the overall outlook remains positive.
